Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of intracisternal VTx-002 in adults with amyotrophic lateral sclerosis
NL-OMON61030Phase 2Recruiting
- Sponsor
- VectorY Therapeutics
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tamuzimod in amyotrophic lateral sclerosis (ALS), sponsored by VectorY Therapeutics. Primary endpoints: Treatment-emergent adverse events, Laboratory safety assessments and 4 more. Started Jun 2026; status: recruiting.
02
Drugs
tamuzimod
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON61030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61030.